© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
December 13, 2009
For patients with early breast cancer, peripheral neurotoxicity is an unfortunate side effect of treatment with taxanes, but there may be a silver lining.
December 12, 2009
The multi-targeted kinase inhibitor sorafenib, approved to treat kidney and liver cancer, may also benefit patients with metastatic breast cancer.
December 11, 2009
The RANK ligand inhibitor denosumab was better than the standard-of-care bisphosphonate, zoledronic acid in breast cancer patients with bone metastases.
December 08, 2009
Cancer patients are at high risk for venous thromboembolism (VTE), a leading cause of death in patients with cancer. Fixed-dose dabigatran may be a replacement for warfarin in the treatment of VTE, according to results of the large Phase III RE-COVER trial.